A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
لماذا يهم هذا الخبر؟
سيظهر الملخص التحليلي هنا بعد اكتمال معالجة الذكاء الاصطناعي.
سياق الخبر
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.
فتح الخبر الأصلي
